Browsing by author "Huddart, Robert"
Now showing items 1-20 of 118
-
A Canadian approach to the regionalization of testis cancer: A review.
Nason, GJ; Wood, LA; Huddart, RA; Albers, P; Rendon, RA; et al. (2020-10)At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of testis cancer care were discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, ... -
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith, TAD; West, CML; Joseph, N; Lane, B; Irlam-Jones, J; et al. (ELSEVIER, 2024-02-21)BACKGROUND: BC2001 showed combining chemotherapy (5-FU + mitomycin-C) with radiotherapy improves loco-regional disease-free survival in patients with muscle-invasive bladder cancer (MIBC). We previously showed a 24-gene ... -
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer.
Portner, R; Bajaj, A; Elumalai, T; Huddart, R; Murthy, V; et al. (ELSEVIER IRELAND LTD, 2021-08-19)Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC). TMT comprises of transurethral resection ... -
A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)
Huddart, RA; Gabe, R; Cafferty, FH; Pollock, P; White, JD; et al. (2015-03-01) -
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Jones, R; Crabb, S; Chester, J; Elliott, T; Huddart, R; et al. (WILEY, 2020-05-19)OBJECTIVES: To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the ... -
A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
Shamash, J; Sarker, S-J; Huddart, R; Harland, S; Joffe, JK; et al. (OXFORD UNIV PRESS, 2017-06-01)BACKGROUND: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of bleomycin ... -
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
Macinnis, RJ; Antoniou, AC; Eeles, RA; Severi, G; Al Olama, AA; et al. (WILEY, 2011-07-18)Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such ... -
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Huddart, R; Hafeez, S; Omar, A; Alonzi, R; Birtle, A; et al. (ELSEVIER SCIENCE LONDON, 2023-05-01)AIMS: Adding concurrent (chemo)therapy to radiotherapy improves outcomes for muscle-invasive bladder cancer patients. A recent meta-analysis showed superior invasive locoregional disease control for a hypofractionated 55 ... -
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Hussain, SA; Lester, JF; Jackson, R; Gornall, M; Qureshi, M; et al. (ELSEVIER SCIENCE INC, 2022-05-01)BACKGROUND: Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival ... -
Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.
Huddart, RA; Reid, AM (HINDAWI LTD, 2018-01-01)Testicular germ cell tumours are the commonest tumours of young men and are broadly managed either as pure seminomas or as 'nonseminomas'. The management of Stage 1 nonseminomatous germ cell tumours (NSGCTs), beyond surgical ... -
Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER).
Hafeez, S; Lewis, R; Hall, E; Huddart, R; RAIDER Trial Management Group, (ELSEVIER SCIENCE LONDON, 2021-05-07) -
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; et al. (HARBORSIDE PRESS, 2019-05-01)BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ... -
Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis.
Hafeez, S; Koh, M; Jones, K; El Ghzal, A; D'Arcy, J; et al. (ELSEVIER SCIENCE LONDON, 2022-05-06)AIMS: Radiotherapy with radiosensitisation offers opportunity for cure with organ preservation in muscle-invasive bladder cancer (MIBC). Treatment response assessment and follow-up are reliant on regular endoscopic evaluation ... -
Bladder Radiotherapy: Is Cinderella Ready for the Ball?
Huddart, RA (ELSEVIER SCIENCE LONDON, 2021-06-01) -
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; et al. (ELSEVIER SCIENCE BV, 2019-04-01)BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ... -
Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges.
Payne, H; Adamson, A; Bahl, A; Borwell, J; Dodds, D; et al. (WILEY, 2013-11-01)• To review the published data on predisposing risk factors for cancer treatment-induced haemorrhagic cystitis (HC) and the evidence for the different preventive and therapeutic measures that have been used in order to ... -
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall, E; Hussain, SA; Porta, N; Lewis, R; Crundwell, M; et al. (ELSEVIER, 2022-05-13)BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy ... -
Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
Tan, MP; Attard, G; Huddart, RA (MDPI, 2018-08-29)Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to ... -
Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
El Charif, O; Mapes, B; Trendowski, MR; Wheeler, HE; Wing, C; et al. (AMER ASSOC CANCER RESEARCH, 2019-07-01)PURPOSE: Cisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom perception of sound. Our purpose was to identify the clinical and genetic determinants of tinnitus among testicular cancer survivors ... -
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart, RA; Birtle, A; Maynard, L; Beresford, M; Blazeby, J; et al. (WILEY, 2017-11-01)OBJECTIVES: To test the feasibility of a randomised trial in muscle-invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy (RC) or selective ...